Rare incidence of T cell lymphomas after chimeric antigen receptor (CAR)-T cell therapy

Fahmia Feroz, Dr. Shakir Rasool
Assistant Professor, Department of Medical Laboratory Science, University School of Allied Health Sciences, Lamrin Tech Skills University, Punjab, India .
Assistant Professor, Department of Physiotherapy, University School of Allied Health Sciences, Lamrin Tech Skills University, Punjab, India .

Abstract: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematologic malignancies, particularly B-cell lymphomas and leukemias[1]. By genetically modifying a patient's T cells to express receptors targeting specific cancer antigens, CAR-T therapy enhances the immune system's ability to recognize and eliminate cancer cells. While CAR-T therapy has demonstrated significant efficacy, its application in T-cell malignancies presents unique challenges[2]. T-cell lymphomas, such as peripheral T-cell lymphoma and cutaneous T-cell lymphoma, are less common and more difficult to treat. The primary obstacle is the phenomenon of fratricide," where engineered CAR-T cells inadvertently target and destroy other T cells, including both malignant and normal ones[3]. This unintended destruction can hinder the expansion and persistence of CAR-T cells within the patient, potentially compromising the therapy's effectiveness.

Keywords: Chimeric Antigen Receptor, hematologic malignancies, B-cell lymphomas, T-cell malignancies, fratricide.

INTRODUCTION

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies, demonstrating remarkable success in B-cell leukemias and lymphomas[4]. By genetically engineering autologous or allogeneic T cells to express receptors that specifically target tumor-associated antigens, CAR-T therapy enhances the immune system's ability to recognize and eliminate malignant cells[5]. This precision-driven approach has provided a new therapeutic avenue for patients with refractory or relapsed cancers, offering significant survival benefits.

Despite its transformative potential, CAR-T cell therapy is not without limitations. Most studies and clinical applications focus on B-cell malignancies due to the availability of well-defined target antigens like CD19 and CD20[6]. However, its application in T-cell malignancies, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), presents unique challenges. One major issue is "fratricide," where CAR-T cells inadvertently target other T cells, including themselves, due to shared antigen expression[7]. Additionally, the therapy's long-term safety profile is still being elucidated, with secondary malignancies emerging as a rare but concerning complication.

Recent reports of T-cell lymphomas occurring after CAR-T cell therapy, though rare, raise important questions about potential mechanisms[8]. These may include clonal selection pressures, inadvertent transformation of infused CAR-T cells, or immune dysregulation induced by the therapy. Understanding these events is critical to improving the safety and efficacy of CAR-T therapy, particularly in the context of T-cell malignancies[9].

This research aims to explore the rare incidence of T-cell lymphomas following CAR-T therapy, examining potential biological mechanisms, clinical characteristics, and implications for future therapeutic development[10]. Addressing these issues will not only enhance our understanding of CAR-T cell therapy's risks but also contribute to the optimization of its use in diverse oncologic settings[11].

FDA Approved CAR-T Cell Therapies

Name	Target Antigen	Brand	FDA Approval	Indication
Tisagenlecleucel	CD19	Kymriah	August 2017 May 2018	r/r B-cell precursor ALL, r/r large B-cell lymphoma
Axicabtagene Ciloleucel	CD19	Yescarta	October 2017 March 2021	r/r large B-cell lymphoma r/r follicular lymphoma

Brexucabtagene autoleucel	CD19	Tecartus	July 2020 October 2021	r/r MCL (July 2020) r/r B-cell precursor ALL(Oct2021)
Lisocabtagene maraleucel	CD19	Breyanzi	February 2021	r/r large B-cell lymphoma
Idecabtagene Vicleucel	BCMA	Abecma	March 2021	r/r MM
Ciltacabtagene autoleucel	BCMA	Carvykti	February 2022	r/r MM

CAR T-cell therapy: A "living drug"

CAR T cells are the equivalent of "giving patients a living drug," As their name implies, T cells—which help orchestrate the immune response and directly kill cells infected by pathogens—are the backbone of CAR T-cell therapy[12]. Currently available CAR T-cell therapies are customized for each individual patient. They are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells[13].

CAR T-Cell Therapy



This diagram illustrates the collection of T cells, their genetic modification to express CARs, expansion in the laboratory, and subsequent infusion into the patient, culminating in the targeted attack on cancer cells. These receptors are "synthetic molecules, they don't exist naturally," After the revamped T cells are “expanded” into the millions in the laboratory, they’re then infused back into the patient[14]. If all goes as planned, the CAR T cells will continue to multiply in the patient's body and, with guidance from their engineered receptor, recognize and kill any cancer cells that harbor the target antigen on their surfaces.

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a form of immunotherapy that involves modifying a patient's T cells to better recognize and attack cancer cells[15]. The process of creating CAR-T cells typically involves several key steps:

1. Collection: T cells are extracted from the patient's blood through a procedure called leukapheresis.
2. Modification: In a laboratory, these T cells are genetically engineered to express chimeric antigen receptors (CARs) on their surface. These receptors are designed to target specific proteins found on cancer cells.
3. Expansion: The modified T cells are then multiplied to produce sufficient quantities for treatment.
4. Infusion: After a preparative regimen, the engineered CAR-T cells are infused back into the patient's bloodstream, where they seek out and destroy cancer cells.

MATERIALS AND METHODOLOGY

Study Design

This study is a retrospective analysis of clinical cases and literature review focusing on the rare incidence of T-cell lymphomas following Chimeric Antigen Receptor (CAR)-T cell therapy[16]. Data were collected from both primary sources (clinical case reports) and secondary sources (published literature), supplemented by laboratory investigations where applicable[17].

Patient Selection and Data Collection

Inclusion Criteria:

- Patients who underwent CAR-T cell therapy for hematologic malignancies.
- Documented cases of T-cell lymphoma development post-CAR-T therapy.
- Availability of clinical, histopathological, and molecular data.

Exclusion Criteria:

- Patients with incomplete follow-up or insufficient documentation of secondary malignancies.
- Cases where secondary malignancies were unrelated to CAR-T therapy[18].
- Data points collected included demographic details, CAR-T cell product used, disease type and stage, therapeutic outcomes, and any subsequent malignancy characteristics.

Laboratory Analysis

- Histopathological Examination:

  Tissue samples of secondary lymphomas were examined using standard staining and immunohistochemistry (IHC) techniques to confirm the diagnosis and identify specific antigen expression profiles[19].

- Molecular Analysis:

  - Next-generation sequencing (NGS) was employed to detect clonal rearrangements in T-cell receptor (TCR) genes and assess genetic alterations in CAR-T cells[20].
  - Polymerase chain reaction (PCR) and flow cytometry were utilized to monitor residual CAR-T cells and detect abnormal expansion or transformation[21].

CAR-T Cell Analysis

CAR-T cells retrieved from patients with secondary T-cell lymphoma were analyzed to investigate[22]:

1. Aberrant genetic modifications during manufacturing.
2. Persistent CAR expression and potential transformation.
3. Clonal expansion or survival of modified T cells.

LITERATURE REVIEW

A systematic review of the literature was conducted using databases like PubMed, Scopus, and Web of Science to identify reported cases of T-cell lymphoma following CAR-T therapy. Keywords included "CAR-T cell therapy," "T-cell lymphoma," "secondary malignancies," and "post-CAR-T complications." Relevant articles were screened, and data were extracted to compare with observed clinical cases[23].

Statistical Analysis

Descriptive statistics were used to summarize demographic and clinical data. Comparative analyses were performed between patients who developed secondary malignancies and those who did not[24]. Kaplan-Meier survival curves were plotted to assess outcomes, and regression analyses were conducted to identify potential risk factors.

Ethical Considerations

This study adhered to ethical guidelines for human research. Institutional Review Board (IRB) approval was obtained for retrospective data collection. Patient consent was waived for anonymized data analysis in compliance with ethical standards[25].

By employing this robust methodology, this study aims to provide a comprehensive understanding of the mechanisms, risk factors, and clinical implications of T-cell lymphomas following CAR-T cell therapy[26].

Discussion: The emergence of T-cell lymphomas following Chimeric Antigen Receptor (CAR)-T cell therapy, although rare, highlights critical safety considerations in the clinical use of this groundbreaking immunotherapy. Below, we discuss the biological mechanisms, clinical implications, and future directions, supported by tabulated summaries[27].

Mechanisms Underlying Secondary T-cell Lymphomas

The development of secondary T-cell lymphomas post-CAR-T therapy may involve several mechanisms. These include pre-existing clonal abnormalities, insertional mutagenesis, immune dysregulation, and antigen specificity issues. Table 1 summarizes the hypothesized mechanisms and supporting evidence[28].

Table 1: Potential Mechanisms of Secondary T-cell Lymphomas

Mechanism	Description	Supporting Evidence	Clinical Implications
Clonal Selection	Expansion of pre-existing malignant clones during CAR-T cell manufacturing	Case reports identifying clonal dominance	Requires enhanced pre-treatment screening

Insertional Mutagenesis	CAR integration causing genetic transformation	Rare in clinical studies	Engineering CAR-T cells with safer vectors
Immune Dysregulation	Loss of immune surveillance due to therapy-induced cytokine imbalance	Increased susceptibility to secondary cancers	Post-treatment immune monitoring is critical
On-target, Off-tumor Effect	CAR-T targeting shared antigens on normal T cells	Observed fratricide in T-cell malignancies	Optimize antigen specificity in CAR design

Clinical Characteristics of Reported Cases

Documented cases of secondary T-cell lymphomas post-CAR-T therapy often share specific clinical and molecular characteristics. Table 2 compares patient demographics, CAR-T cell types, and lymphoma features in reported cases[29].

Table 2: Characteristics of Secondary T-cell Lymphomas

Parameter	Case 1	Case 2	Case 3	Observations
Age (years)	45	52	38	Adults predominantly affected
CAR-T Target Antigen	CD19	CD22	CD19	Commonly used antigens in B-cell therapies
Time to Lymphoma Onset (months)	18	24	14	Long latency period
Lymphoma Subtype	PTCL	CTCL	PTCL	Peripheral and cutaneous T-cell lymphomas
Outcome	Progressive disease	Stable disease	Responded to therapy	Varied clinical responses

Strategies for Risk Mitigation

Proactive strategies to mitigate the risk of secondary T-cell lymphomas involve improving CAR-T cell production processes, optimizing CAR designs, and instituting rigorous post-treatment surveillance. Table 3 highlights these strategies[30].

Table 3: Risk Mitigation Strategies

Strategy	Description	Current Challenges	Potential Solutions
Pre-manufacturing Screening	Identify malignant clones in patient-derived T cells	Requires advanced diagnostic tools	Use high-throughput sequencing or NGS
CAR-T Engineering Enhancements	Optimize antigen specificity to reduce fratricide	Limited availability of unique targets	Identify tumor-specific antigens
Safer Genetic Engineering Approaches	Reduce risk of insertional mutagenesis	Reliance on viral vectors	Use non-viral gene-editing tools like CRISPR
Long-term Surveillance	Monitor for secondary malignancies post-therapy	Cost and patient adherence challenges	Standardized protocols for follow-up care

Future Directions

1. Preclinical Models: Development of robust animal models to study secondary malignancies and optimize CAR design[31].
2. Antigen Refinement: Focus on identifying novel antigens specific to malignant T cells to avoid targeting normal T cells.
3. CAR-T Evolution: Incorporation of self-regulating systems (e.g., "suicide switches") to mitigate risks associated with long-term persistence[32].

4. Multicenter Studies: Collaboration across institutions to collect large datasets for analyzing the incidence and risk factors associated with secondary malignancies[33].

Understanding and managing the side effects of CAR T-cell therapies

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment, particularly for certain hematological malignancies. However, its potent efficacy is accompanied by potential side effects that require careful management[34].

Common Side Effects:

1. Cytokine Release Syndrome (CRS): CRS is a frequent and potentially severe side effect characterized by high fever, fatigue, nausea, and in severe cases, organ dysfunction. It results from the rapid activation and proliferation of CAR T-cells, leading to a surge of inflammatory cytokines. Management includes supportive care and, in severe instances, administration of tocilizumab, an anti-IL-6 receptor antibody[35].
2. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Patients may experience neurological symptoms such as confusion, delirium, expressive aphasia, and seizures. Monitoring and, if necessary, interventions like corticosteroids are essential for managing ICANS[36].
3. Infections: The therapy can lead to a weakened immune system, increasing susceptibility to infections. Preventive measures include prophylactic antibiotics and close monitoring for signs of infection[37].
4. B-cell Aplasia: Targeting CD19 can result in the depletion of healthy B-cells, leading to hypogammaglobulinemia and an increased risk of infections. Regular immunoglobulin replacement therapy may be necessary[38].
5. Cytopenias: Low blood cell counts can cause fatigue, increased bleeding risk, and heightened infection susceptibility. Management involves blood transfusions and growth factor support[39].

CONCLUSION

The rare occurrence of T-cell lymphomas following Chimeric Antigen Receptor (CAR)-T cell therapy represents a critical challenge in the advancement of this transformative immunotherapy[40]. While CAR-T cell therapy has demonstrated substantial success in treating B-cell malignancies, its application in T-cell cancers and the emergence of secondary malignancies necessitate a deeper understanding of associated risks[41].

The mechanisms contributing to these secondary malignancies likely involve a combination of clonal selection, insertional mutagenesis, immune dysregulation, and on-target, off-tumor effects[42]. Though the incidence remains low, the implications for patient safety and therapeutic efficacy are significant[43]. Enhancing pre-treatment screening, improving CAR-T cell manufacturing processes, and incorporating novel design elements such as tumor-specific antigen targeting and self-regulating systems are essential steps toward mitigating these risks[44].

Furthermore, this study underscores the importance of long-term surveillance to detect secondary malignancies early and ensure timely intervention[45]. Multicentre collaborations and standardized protocols will be pivotal in addressing knowledge gaps and optimizing CAR-T therapy for broader and safer application[46].

In conclusion, while secondary T-cell lymphomas are rare, their occurrence highlights the need for ongoing research and innovation to improve the safety profile of CAR-T cell therapy[47]. Addressing these challenges will expand the potential of CAR-T therapy, ultimately enhancing its applicability and benefit for patients with complex malignancies.

REFERENCES

[1] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. [PubMed: 26980727]

[2] Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–2045. [PubMed: 20548096]

[3] 3.Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemoimmunotherapy in diffuse large B cell

lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1729–1736. [PubMed: 25008330]

[4] Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261–2271. [PubMed: 18509084]

[5] Sterner, R. & Kenderian, S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr. Opin. in Hematol. 27, 41–48 (2020).

[6] Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, 1 (2018)

[7] Green, D. J. et al. Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood. 132, 1011–1011 (2018).

[8] Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poorprognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267–2280 (2018).

[9] Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210–2221 (2019).

[10] Lin, Q., Zhao, J., Song, Y. & Liu, D. Recent updates on CAR T clinical trials for multiple myeloma. Mol. Cancer. 18, 154 (2019)

[11] Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J. of Hematol. & Oncol. 13, 30 (2020).

[12] Du, H. et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 35, 221–237.e8 (2019)

[13] Mata, M. et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 7, 1306–1319 (2017)

[14] Liu, G. et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur. J. Immunol. 50, 712–724 (2020).

[15] Jin, L. et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.Nat. Commun. 10, 4016 (2019)

[16] Sterner, R. & Kenderian, S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr. Opin. in Hematol. 27, 41–48 (2020)

[17] Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018)

[18] Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 36, 471–482 (2019).

[19] Jonnalagadda, M. et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid Fc receptor binding and improve t cell persistence and antitumor efficacy. Mol. Ther. 23, 757–768 (2015).

[20] Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571–581 (2017).

[21] Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731–738 (2018).

[22] Roex, G. et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J. of Hematol. & Oncol. 13, 164 (2020)

[23] Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. of Med. 378, 449–459 (2018)

[24] Maroufi NF, Vahedian V, Hemati S, et al. Targeting cancer stem cells by melatonin: effective therapy for cancer treatment. Pathol Res Pract. 2020; 216(5):152919.

[25] Chachaj A, Wiśniewski J, Rybka J, et al. Asymmetric and symmetric dimethylarginines and mortality in patients

with hematological malignancies: a prospective study. PLoS One. 2018; 13(5):e0197148.

[26] Astamal RV, Maghoul A, Taefehshokr S, et al. Regulatory role of microRNAs in cancer through hippo signaling pathway. Pathol Res Pract. 2020; 216(12):153241.

[27] Roex G, Feys T, Beguin Y, et al. Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics. 2020; 12(2): 194.

[28] Isazadeh A, Hajazimian S, Garshasbi H, et al. Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: focus on myeloma. J Cell Physiol. 2021; 236(2): 791-805.

[29] Lei M, Kim EB, Branagan A, Lou U, Zemel M, Raje N. Current management and emerging treatment strategies for multiple myeloma. Rinsho Ketsueki. 2019; 60(9): 1243-1256.

[30] Yan W, Liu Z, Liu J, Xia Y, Hu K, Yu J. Application of chimeric antigen receptor T cells in the treatment of hematological malignancies. Biomed Res Int. 2020; 2020: 1-9.

[31] Goldsmith SR, Ghobadi A, DiPersio JF. Hematopoeitic cell transplantation and CAR T-cell therapy: complements or competitors? Front Oncol. 2020; 10: 2904.

[32] Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015; 36(8): 494-502.

[33] Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med. 2015; 240(8): 1087-1098.

[34] Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomarker Res. 2017; 5(1): 1-6.

[35] Curran KJ, Seinstra BA, Nikhamin Y, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015; 23(4): 769-778.

[36] Chmielewski M, Hombach AA, Abken H. Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014 Jan; 257(1): 83-90.

[37] Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25): 3322-3331.

[38] O'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019; 25(4): 1142-1146.

[39] Palomba ML, Qualls D, Monette S, et al. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. J Immunother Cancer. 2022; 10(2):e004128.

[40] Nguyen A, Johanning G, Shi Y. Emerging novel combined CAR-T cell therapies. Cancer. 2022; 14(6): 1403.

[41] Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A review of clinical outcomes of CAR T-cell therapies for b-acute lymphoblastic leukemia. Int J Mol Sci. 2021; 22(4): 2150.

[42] Jain N, O'Brien S. Targeted therapies for CLL: practical issues with the changing treatment paradigm. Blood Rev. 2016; 30(3): 233-244.

[43] Grupp SA, Laetsch TW, Buechner J, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016; 128(22): 221.

[44] Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011(1): 110-118.

[45] Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020; 135(19): 1650-1660.

[46] Rennert PD, Dufort FJ, Su L, et al. Anti-CD19 CAR T cells that secrete a Biparatopic anti-CLEC12A bridging protein have potent activity against highly aggressive acute myeloid leukemia in vitro and in vivo. Mol Cancer Ther. 2021; 20(10): 2071-2081.